The FDA requested that Novo take immediate action to address the violations, which could include ceasing all ads containing misleading claims about the pill.
Asianet Newsable on MSN
FDA says Novo's Wegovy pill TV advertisement is misleading: NVO stock pares gains
According to an FDA letter dated February 5, the agency stated that the advertisement “misbrands” Wegovy.
Feb 9 (Reuters) - The U.S. Food and Drug Administration said a television advertisement for Novo Nordisk's weight-loss pill is "false or misleading," according to a letter dated February 5. The health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results